Archives: 2020-09-10

Convalescent plasma fails to improve outcome of COVID-19 in PLACID trial. Limits of the study.

The COVID-19 pandemic is still raging in India, with over 4.5 million cases, 75.000 deaths and more than 90,000 new cases a day. At present there are few effective therapeutic options, which means that healthcare providers are faced with ongoing challenges in managing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A new study based

Read More

SARS-CoV-2 ORF3b is a potent interferon antagonist and its activity is increased by a naturally occurring elongation variant

One of the features distinguishing SARS-CoV-2 from its more pathogenic counterpart SARS-CoV is the presence of premature stop codons in its ORF3b gene. In this paper it’s shown that SARS-CoV-2 ORF3b is a potent interferon antagonist, suppressing the induction of type I interferon more efficiently than its SARS-CoV ortholog. Phylogenetic analyses and functional assays reveal

Read More

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. Results of a WHO Meta-analysis

Treating critically ill COVID-19 patients with corticosteroid drugs reduces the risk of death by 20 percent, an analysis of seven international trials found on Wednesday, prompting the World Health Organization to update its advice on treatment. The analysis — which pooled data from separate trials of low dose hydrocortisone, dexamethasone and methylprednisolone — found that steroids improve survival

Read More